Comparative Pharmacology
Head-to-head clinical analysis: DUVOID versus PROVOCHOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUVOID versus PROVOCHOLINE.
DUVOID vs PROVOCHOLINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-1A adrenergic receptor antagonist; relaxes smooth muscle in the bladder neck and prostate, reducing outflow resistance.
Parasympathomimetic agent that acts as a direct cholinergic agonist at muscarinic receptors, increasing exocrine gland secretion.
100 mg orally three times daily.
Subcutaneous: 2.5-5 mg; if no response, repeat with 5-10 mg; maximum single dose 10 mg.
None Documented
None Documented
Terminal elimination half-life is 12–15 hours in patients with normal renal function; prolonged to 24 hours or more in moderate-to-severe renal impairment.
Terminal elimination half-life is 1-2 hours in patients with normal renal function. However, due to rapid hydrolysis by plasma and tissue cholinesterases, the actual duration of effect is brief (minutes). Clinical context: half-life may be prolonged in patients with reduced cholinesterase activity or renal impairment.
Renal elimination accounts for approximately 90% of a dose as unchanged drug; biliary/fecal excretion is minor (<10%).
Primarily renal excretion of unchanged drug and inactive metabolites. Approximately 80-90% of administered dose is excreted renally. No significant biliary or fecal elimination.
Category C
Category C
Cholinergic Agonist
Cholinergic Agonist